Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

Inclusion Criteria: * Female subjects with PCO or Polycystic ovary syndrome (PCOS) according to the revised 2003 Rotterdam Consensus * Female subjects suitable for IVF/ICSI, undergoing first or second attempt * 18-35 years old, Body Mass Index (BMI) less than or equal to 32, non-smoking at least from Visit 0 (V0) * Normal FSH value (less than 10 international unit per liter \[IU/L\]) on Day 3 of spontaneous cycle within 12 months prior to the trial * Anti Mullerian Hormone (AMH) value (greater than 1.5 nanogram per milliliter \[ng/mL\]) of a spontaneous cycle within 12 months prior to the trial or at least at V0 * No history of active genito-urinary infection * Normal thyroid function (or adequate substitution for at least 3 months) * Negative cervical papanicolaou test within the last 12 months prior to study entry * No gonadotropins, for at least one month prior to the trial * No metformin therapy for at least one month prior to Visit 1 (V1) * Subject who is able to participate in the trial and has provided written, informed consent. Exclusion Criteria: * Ongoing pregnancy, any pregnancy within 3 months prior to study entry, or any contraindication to pregnancy or carrying pregnancy to term * Drilling 3 months prior to V0 * Uterine malformation, diethylstilbestrol syndrome, synechia * Female subjects with World Health Organization (WHO) Type I or III anovulation * Female subjects with hyperprolactinemia * Female subjects with more than 2 recurrent miscarriages (early or late, and for any reasons) * Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus, for subject or partner * Abnormal gynecological bleeding of undetermined origin * History of major thromboembolic disease * Endometriosis (Grade III or IV) * Presence or history of malignant tumors and related treatment * Known case of tumors of the hypothalamus or pituitary gland * Clinically significant systemic disease or clinically significant abnormal hematology, chemistry, or urinalysis results at screening * Known allergic reaction or hypersensitivity to Cetrotide® or Ovitrelle® * Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years * Participation in another clinical trial within 3 months prior to study entry.